中国生物工程杂志

As the most common gynecological malignancy, cervical cancer (human papilloma virus, HPV) is the second largest threat to women’s health. Cervical cancer vaccine is an effective way to prevent cervical cancer. Glaxosmithkline (GSK) and Merck (MSD) dominated the global market for cervical cancer vaccines until 2019. Despite the late start of cervical cancer vaccines in China, 20 vaccines have entered the clinical stage driven by domestic innovation policies. In particular, Cecolin, which is developed by INNOVAX and Xiamen University, was approved for market by National Drug Administration in April 2020. It is the first domestically developed cervical cancer vaccine in China and the third in the world. Compared with Europe and the United States and other developed countries, there is still a big gap in the promotion of cervical cancer vaccine in China, the HPV vaccine coverage rate of 9-45 years old women in China is less than 0.05%. In view of the low coverage rate of HPV vaccination, some countermeasures and suggestions were put forward, such as optimizing the review and approval process of HPV vaccine, including HPV vaccine into the national immunization program, and improving women’s understanding of HPV vaccine.